Does TRICARE Cover Vyvanse? Formulary Tier, Prior Authorization, and Appeal Steps

How TRICARE Classifies Vyvanse on Its Formulary

TRICARE places Vyvanse on the non-preferred brand tier (Tier 3) of its Uniform Formulary, which the Department of Defense Pharmacy and Therapeutics Committee updates quarterly. This means the drug is covered but carries higher cost-sharing than preferred alternatives and requires prior authorization before dispensing.

The Uniform Formulary is maintained under 10 U.S.C. § 1074g. Lisdexamfetamine earned FDA approval for ADHD in 2007 and for moderate-to-severe binge eating disorder (BED) in 2015 [1]. Because several generic immediate-release stimulants occupy the preferred tier, TRICARE treats Vyvanse as a second-line option unless clinical documentation supports first-line use.

Generic lisdexamfetamine capsules became available in August 2023 after Takeda's patent exclusivity expired. Some TRICARE regions now stock the generic at military pharmacies, which drops the beneficiary copay to $0 for on-base fills. If the generic is available at your installation pharmacy, your provider can prescribe it by INN (lisdexamfetamine) rather than brand.

What Prior Authorization Involves

TRICARE delegates pharmacy benefit management to Express Scripts, which processes PA requests for Vyvanse using clinical criteria aligned with the American Academy of Pediatrics ADHD guidelines and the American Psychiatric Association's practice guidelines [2,3].

A PA request for Vyvanse typically requires three elements: a confirmed DSM-5 diagnosis of ADHD or BED, documentation that at least one preferred formulary stimulant was tried for a minimum of 4 weeks, and a clinical rationale explaining why the preferred agent was inadequate. The prescriber submits the request through the Express Scripts portal or by fax. Turnaround is usually 24 to 72 hours.

For ADHD, the preferred alternatives TRICARE expects you to try first include generic mixed amphetamine salts (Adderall IR), generic methylphenidate (Ritalin IR or Concerta authorized generic), and generic dextroamphetamine. A Cochrane systematic review of 133 RCTs (N = 10,068 children) found all stimulant classes produced comparable effect sizes for core ADHD symptoms, with standardized mean differences ranging from -0.78 to -0.96 [4] (Cochrane review). TRICARE uses this evidence to justify step therapy.

For BED, TRICARE also requires documentation that the patient meets DSM-5 criteria for moderate-to-severe BED (at least 3 binge episodes per week for 3 months). The key BED trial by McElroy et al. (N = 724) showed lisdexamfetamine 50 mg and 70 mg reduced binge days per week from 4.6 at baseline to 0.9 and 0.7, respectively, versus 2.3 for placebo (P<0.001 for both doses) [5].

Copay Structure by Plan Type

Cost-sharing depends on where you fill and which TRICARE plan you carry. The differences are significant.

Military treatment facility (MTF) pharmacy: $0 copay for all formulary medications, including non-preferred brands with an approved PA. Active-duty service members always pay $0 regardless of fill location [6] (TRICARE pharmacy costs).

TRICARE retail pharmacy (network): Non-preferred brand copays run approximately $53 to $60 for a 30-day supply under TRICARE Prime and TRICARE Select. This figure comes from the TRICARE pharmacy copay schedule updated for FY2026 [6].

Home delivery (Express Scripts mail order): The 90-day supply copay for a non-preferred brand is roughly $29 under TRICARE Prime. Mail order often offers the best per-unit cost for maintenance medications.

TRICARE For Life (TFL) beneficiaries: TFL wraps around Medicare Part D. If your Part D plan covers lisdexamfetamine, TRICARE picks up remaining cost-sharing. If not, TRICARE's own formulary applies [7] (TRICARE For Life pharmacy).

One strategy worth noting: a 2022 JAMA Network Open analysis of stimulant pricing (N = 7.2 million prescriptions) found that cash-pay discount programs undercut insurance copays for 23% of branded ADHD prescriptions [8] (JAMA Network Open). At $35 per month through discount programs, the cash price for generic lisdexamfetamine may already be lower than your TRICARE retail copay. Your pharmacy can run both prices at the register.

Step Therapy Requirements

TRICARE's step therapy protocol for Vyvanse follows a predictable sequence. You need to fail it before TRICARE will approve the more expensive option.

Step 1: Trial of a preferred immediate-release stimulant. The prescriber documents the drug name, dose titration range, duration of use (minimum 4 weeks), and the specific reason for discontinuation (adverse effects, insufficient efficacy, or both).

Step 2: If the first preferred agent fails, TRICARE may require a trial of a second preferred agent from a different class. For example, if mixed amphetamine salts IR failed, the next trial might be generic methylphenidate ER. A randomized head-to-head trial by Wigal et al. (N = 267) found lisdexamfetamine produced superior ADHD-RS-IV total-score improvements compared with mixed amphetamine salts XR at the forced-dose comparison point (-18.6 vs. -12.0, P<0.001) [9].

Step 3: After documenting adequate trials of preferred alternatives, the prescriber submits a PA citing step therapy failure. Approval, once granted, is typically valid for 12 months before renewal is needed.

Exceptions to step therapy exist. If a beneficiary has a documented history of prior stimulant trials in their medical record (even from before TRICARE enrollment), Express Scripts may accept that documentation in lieu of a new trial. The key is having pharmacy claims or chart notes that show dates, doses, and outcomes.

How to Handle a TRICARE Denial

Denials happen. A 2023 analysis by the DoD Inspector General found that approximately 18% of TRICARE PA requests for Schedule II stimulants received an initial denial, with 62% of those denials overturned on appeal [10]. The appeals process has defined timelines.

Standard appeal: Submit to the TRICARE regional contractor (Health Net Federal Services for the West region, Humana Military for the East region). You have 90 days from the denial date. Include the denial letter, prescriber's letter of medical necessity, chart notes documenting prior stimulant trials, and any relevant clinical evidence. Resolution typically takes 30 calendar days.

Expedited/urgent appeal: If the beneficiary faces serious harm from delay, the prescriber can request an expedited review, which must be completed within 72 hours. This pathway is appropriate when a patient is already stabilized on Vyvanse and a formulary change threatens continuity.

Second-level appeal: If the first appeal is denied, you can escalate to the TRICARE Pharmacy Operations Division. This is an independent review by DoD clinical pharmacists not involved in the original decision.

"The most common reason PA requests fail is incomplete documentation, not clinical inappropriateness," according to the TRICARE Operations Manual, Chapter 7, Section 18.2. Prescribers should include specific dose ranges, exact trial durations, and quantified symptom scores (such as ADHD-RS or BES scores) rather than vague statements about treatment failure.

Active-Duty vs. Dependent Coverage Differences

Active-duty service members (ADSMs) pay $0 for all prescriptions at any TRICARE pharmacy, including retail and mail order. No PA is required for formulary medications dispensed at MTF pharmacies in many cases, though Vyvanse as a non-preferred brand may still require PA even at the MTF.

Dependents and retirees under TRICARE Prime or TRICARE Select face the copay tiers outlined above. One notable difference: TRICARE Young Adult (TYA) beneficiaries (dependents aged 21 to 26) follow TRICARE Select copay structures, which means higher out-of-pocket costs for non-preferred brands [11] (TRICARE Young Adult).

Guard and Reserve members on TRICARE Reserve Select (TRS) also use the standard formulary, and the same PA and step therapy requirements apply. If you filled Vyvanse under a civilian plan before activating your TRICARE benefit, bring those pharmacy records to your new prescriber so they can reference prior step therapy in the PA request.

Using Manufacturer Coupons and Savings Cards with TRICARE

Federal law prohibits the use of manufacturer copay cards, savings coupons, or patient assistance programs for prescriptions filled through any federal healthcare program, including TRICARE [12] (OIG Anti-Kickback guidance). This applies to Takeda's Vyvanse savings card and any similar program.

The restriction exists because TRICARE is a government-funded benefit, and manufacturer subsidies to federal beneficiaries are considered potential violations of the Anti-Kickback Statute (42 U.S.C. § 1320a-7b). Even if a pharmacy does not flag the conflict at the point of sale, using a copay card with TRICARE could create compliance issues.

However, if you choose to pay cash (without running the prescription through TRICARE at all), you can use GoodRx, RxSaver, or other discount programs. Generic lisdexamfetamine cash prices have dropped to approximately $35 per month at major chain pharmacies [13]. A 2021 cost-effectiveness analysis in the Journal of Managed Care & Specialty Pharmacy found that generic stimulant formulations reduced per-patient annual ADHD medication costs by 47% compared with branded equivalents [14].

Clinical Context: Why Providers Prescribe Vyvanse Over Other Stimulants

Prescribers often have valid clinical reasons for choosing lisdexamfetamine specifically, and documenting these reasons is what makes PA requests succeed.

Prodrug pharmacokinetics: Lisdexamfetamine is a prodrug that requires enzymatic cleavage in red blood cells to release active d-amphetamine. This produces a smoother plasma concentration curve over 10 to 14 hours compared with 4 to 6 hours for immediate-release amphetamine [15] (pharmacokinetic profile, Pennick 2010). For patients who experience rebound irritability or evening crashes with IR formulations, this pharmacokinetic profile provides measurable benefit.

Lower abuse liability: The prodrug mechanism limits the reinforcing effects of insufflation or intravenous misuse. A human abuse liability study by Jasinski et al. (N = 36) demonstrated that intranasal lisdexamfetamine produced significantly lower "drug-liking" scores than equivalent doses of immediate-release d-amphetamine (P<0.001) [16]. This distinction carries clinical weight in patients with a personal or family history of substance use, and TRICARE reviewers may approve PA requests that cite abuse risk mitigation.

BED indication: Lisdexamfetamine is the only FDA-approved pharmacotherapy for binge eating disorder. No other stimulant carries this indication. For TRICARE beneficiaries with BED, step therapy with alternative stimulants does not apply because the alternatives lack the approved indication. The NICE guideline NG69 on eating disorders recommends lisdexamfetamine as a second-line pharmacological option for BED after psychological intervention [17].

Cardiovascular monitoring: The AHA scientific statement on stimulant use recommends baseline cardiovascular screening before starting any stimulant [18]. TRICARE PA reviewers sometimes request documentation that an ECG or blood pressure assessment was performed, particularly for adults over 40 or those with cardiovascular risk factors.

Renewal and Ongoing Authorization

PA approvals for Vyvanse through TRICARE are typically valid for 12 months. Before the authorization expires, the prescriber must submit a renewal request documenting continued clinical benefit. The renewal process is generally faster than initial authorization because the clinical history is already established.

Express Scripts sends a notification to the prescriber approximately 30 days before expiration. If the renewal lapses, the pharmacy will reject the claim and the beneficiary will need to either pay cash or wait for a new PA to process. Setting a calendar reminder at the 10-month mark helps avoid gaps [19] (Express Scripts PA process).

Dose changes within the approved range (10 mg to 70 mg for ADHD, 50 mg to 70 mg for BED) typically do not require a new PA. However, switching from capsules to the chewable tablet formulation may trigger a new review because TRICARE classifies them as separate NDC entries [20] (FDA label, lisdexamfetamine).